R. Delva

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

Gwénaëlle Gravis, Karim Fizazi, Florence Joly et al. · The Lancet Oncology · 2013 · 740 citations

Medicine, Oncology, Urology +16

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

Gwénaëlle Gravis, Jean‐Marie Boher, Florence Joly et al. · European Urology · 2015 · 462 citations

Medicine, Oncology, Urology +17

Prevention of Oxaliplatin-Related Neurotoxicity by Calcium and Magnesium Infusions

Laurence Gamelin, M. Boisdron‐Celle, R. Delva et al. · Clinical Cancer Research · 2004 · 343 citations · Full text

Medicine, Oncology, Pharmacology +17

Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer

Érick Gamelin, R. Delva, J H Jacob et al. · Journal of Clinical Oncology · 2008 · 341 citations

Pharmacy, Oncology, Pharmacokinetics +17

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial

Karim Fizazi, Laura Faivre, F. Lesaunier et al. · The Lancet Oncology · 2015 · 238 citations

Medicine, Oncology, Urology +17